查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988446

巨細胞病毒檢測市場：2026-2032年全球市場預測（按產品類型、檢測類型、檢體類型、應用和最終用戶分類）

Cytomegalovirus Tests Market by Product, Test Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，巨細胞病毒檢測市場價值將達到 7.3124 億美元，到 2026 年將成長至 7.8811 億美元，到 2032 年將達到 12.9201 億美元，年複合成長率為 8.47%。

主要市場統計數據
基準年 2025 7.3124億美元
預計年份：2026年 7.8811億美元
預測年份 2032 1,292,010,000 美元
複合年成長率 (%) 8.47%

臨床因素、診斷重點和操作考慮因素的策略整合塑造了現代巨細胞病毒檢測和部署。

隨著診斷技術和治療途徑的進步，巨細胞病毒(CMV) 檢測在臨床和公共衛生領域的重要性日益凸顯。早期準確識別 CMV 感染對於新生兒護理、移植患者管理、捐贈者篩檢和產前風險評估仍然至關重要。隨著對精準診斷和快速照護現場方案的需求不斷成長，臨床、實驗室、研究和商業領域的相關人員需要將技術能力、應用場景優先順序和監管要求清晰整合，以指導投資和營運決策。

分子診斷和即時診斷技術的進步、監管部門對檢驗的日益重視以及檢體的柔軟性正在改變巨細胞病毒檢測的臨床應用。

鉅細胞病毒 (CMV) 檢測領域正經歷多項變革，其驅動力包括技術成熟、臨床重點轉變以及對快速有效檢測結果日益成長的需求。分子擴增技術的靈敏度和處理能力不斷提升，使得在多種檢體基質中實現早期檢測成為可能，並能應對傳統血清學檢測無法涵蓋的更廣泛的臨床場景。同時，即時檢測 (PoC) 和簡化的抗原檢測方法正朝著患者現場應用的方向發展，降低了門診和新生兒病房等需要即時做出治療決策的場所進行及時診斷的門檻。

美國近期關稅措施對巨細胞病毒檢測診斷供應鏈、籌資策略及製造商採購韌性的影響。

美國近期推出的關稅政策進一步加劇了全球診斷組件和設備供應鏈的複雜性。對進口試劑、儀器零件及相關耗材徵收關稅可能會增加製造商和檢查室營運商的總成本，促使他們重新評估籌資策略和庫存管理。對於依賴跨境供應鏈的企業而言，這些措施凸顯了其日益成長的需求，即需要實現採購來源多元化和採用近岸外包方案，以降低關稅相關成本波動帶來的影響。

全面的細分分析揭示了產品模式、測試結果、臨床應用、最終用戶工作流程和檢體基質如何決定診斷的價值和普及程度。

按產品、檢測類型、應用、最終用戶和檢體類型細分鉅細胞病毒 (CMV) 診斷，可以揭示其價值和需求如何因臨床背景和技術特性而異。按產品分類，這些包括抗原檢測、核酸增幅檢查和血清學檢測。抗原檢測方法大致分為螢光和側向層析法，兩者在速度和靈敏度方面各有側重，以滿足不同的需求。螢光通常用於需要更高分析靈敏度的中心檢查室，而側向層析抗原檢測則滿足在患者所在地進行快速篩檢的需求。核酸擴增方法包括數位聚合酵素鏈鎖反應(PCR)、等溫擴增和即時PCR。即時PCR因其在靈敏度、處理能力和法規相容性方面的平衡而仍然是親和性的技術。血清學檢測，包括化學冷光免疫檢測、酵素免疫分析法(ELISA) 和側向流動免疫檢測，可提供有關宿主免疫反應的補充資訊，並在篩檢和流行病學監測中發揮核心作用。

美洲、歐洲、中東和非洲以及亞太地區的診斷環境和基礎設施存在差異，導致各地區的部署路徑各不相同。

區域趨勢影響著技術應用、報銷機制、檢查室基礎設施和臨床指南，從而在不同地區造成了不同的策略挑戰。在美洲，診斷生態系統的特點是檢查室網路完善、分子診斷平台已廣泛應用，以及臨床指引強調對高風險族群進行早期檢測。這些系統評估的檢測方法需具備臨床效用、擴充性和與電子健康記錄的兼容性，同時也要求強大的供應鏈和合規性。

現有平台營運商、專家創新者和通路合作夥伴之間的競爭和策略行動，決定了檢測的可用性和臨床有效性。

鉅細胞病毒 (CMV) 檢測領域的競爭格局呈現出平台型製造商、專業方法開發人員和專注於特定臨床應用的新興創新者三者並存的態勢。成熟的診斷公司往往利用其豐富的產品系列、良好的監管記錄和全球分銷網路，提供從高通量檢測系統到照護現場設備等一系列整合解決方案。這些成熟公司正積極投資於臨床檢驗研究、平台相容性以及生命週期服務契約，以維護客戶忠誠度並滿足醫院和合約實驗室的需求。

為產業主管提供可操作的、高優先順序的行動方案，以提高巨細胞病毒診斷解決方案的臨床可靠性、韌性和普及性。

產業領導者可以採取果斷行動，增強臨床對鉅細胞病毒 (CMV) 檢測的信心，加速其普及，並建立穩健的供應和商業模式。優先進行強力的臨床檢驗研究，以證明其在目標應用領域的效用，將有助於增強支付方和醫療服務提供者的信心。產品設計應符合目標終端使用者的實際情況，例如最大限度地減少診所的工作時間，並確保診斷檢查室的自動化和處理能力，這將降低推廣應用的障礙，並支援其融入臨床工作流程。

採用透明且可重複的研究途徑，結合嚴格的二手文獻綜述、與主要相關人員的訪談以及基於情境的檢驗。

本研究採用實證方法，結合系統性的二手文獻綜述和主導訪談，以確保研究結果的平衡性和可重複性。二手文獻綜述涵蓋了同儕審查的臨床文獻、監管指南文件和技術白皮書，旨在梳理檢測的性能特徵、建議的臨床工作流程和檢驗標準。定性訪談則包括對臨床醫生、實驗室經理、採購經理和技術開發人員的結構化訪談，以獲取關於推廣應用促進因素、營運限制和未滿足需求的第一手觀點。

綜合結論強調，檢驗的創新、營運韌性和實證部署是有效巨細胞病毒診斷策略的支柱。

鉅細胞病毒 (CMV) 診斷是一個動態領域，臨床需求、技術創新和營運要求在此交匯融合。分子擴增和照護現場抗原檢測技術的進步正在拓展 CMV 及時識別的應用場景，從而顯著改善新生兒、移植患者和孕婦的預後。同時，日益嚴格的監管、供應鏈的限制以及區域差異要求研發人員和採用者採取以實證醫學為基礎、靈活且優先考慮臨床效用和服務連續性的策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：巨細胞病毒檢測市場：依產品分類

  • 抗原檢測
    • 螢光
    • 橫向流動化驗
  • 核酸增幅檢查
    • 數位聚合酵素鏈鎖反應
    • 等溫擴增
    • 即時聚合酵素鏈鎖反應
  • 血清學檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 側向流動免疫檢測

第9章：巨細胞病毒檢測市場（依檢測類型分類）

  • 定性
  • 定量

第10章：巨細胞病毒檢測市場（檢體類型分類）

  • 唾液
  • 組織
  • 尿
  • 全血

第11章：巨細胞病毒檢測市場：依應用分類

  • 診斷
  • 捐贈者篩檢
  • 產前檢查
  • 篩檢

第12章：巨細胞病毒檢測市場：依最終用戶分類

  • 診所
  • 檢查室
  • 醫院
  • 研究機構

第13章：巨細胞病毒檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：巨細胞病毒檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：巨細胞病毒檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國巨細胞病毒檢測市場

第17章：中國巨細胞病毒檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbexa Ltd.
  • Abbott Laboratories
  • Accubiotech Co., Ltd
  • AdvaCare Pharma USA
  • Agilent Technologies, Inc.
  • Atlas Medical GmbH
  • Bio-Rad Laboratories, Inc.
  • Biogenix Inc. Pvt. Ltd.
  • CLONIT srl
  • Creative Diagnostics
  • CTK Biotech Inc. by SSI Diagnostica A/S
  • Diasorin SpA
  • Elabscience Bionovation Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hangzhou Realy Tech Co., Ltd.
  • Intec Products, Inc.
  • IQ Products BV
  • Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Thermo Fisher Scientific Inc
Product Code: MRR-6B0EA07975A5

The Cytomegalovirus Tests Market was valued at USD 731.24 million in 2025 and is projected to grow to USD 788.11 million in 2026, with a CAGR of 8.47%, reaching USD 1,292.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 731.24 million
Estimated Year [2026] USD 788.11 million
Forecast Year [2032] USD 1,292.01 million
CAGR (%) 8.47%

A strategic synthesis of clinical drivers, diagnostic priorities, and operational considerations shaping contemporary cytomegalovirus testing and adoption

The clinical and public health implications of cytomegalovirus (CMV) testing have intensified as diagnostic technologies and care pathways evolve. Early and accurate identification of CMV infection remains a cornerstone of neonatal care, transplant patient management, donor screening, and prenatal risk mitigation. With growing emphasis on precision diagnostics and rapid point-of-care solutions, stakeholders across clinical, laboratory, research, and commercial domains require a clear synthesis of technological capabilities, use-case priorities, and regulatory expectations to guide investment and operational decisions.

This executive overview synthesizes current drivers and constraints shaping CMV testing adoption, emphasizing the interplay between assay performance characteristics and real-world clinical requirements. It highlights advances in assay modalities, the implications of regulatory and reimbursement trends, and the operational considerations that determine adoption in diverse end-user settings. By clarifying the diagnostic value proposition across sample types and clinical applications, this introduction sets the stage for deeper analysis of transformative shifts, policy impacts, segmentation-specific insights, and practical recommendations for decision-makers seeking to optimize diagnostic portfolios and clinical pathways.

How advances in molecular and point-of-care diagnostics, regulatory emphasis on validation, and sample flexibility are reshaping clinical adoption of cytomegalovirus testing

The CMV testing landscape is undergoing multiple transformative shifts driven by technological maturation, changing clinical priorities, and evolving expectations for rapid, actionable results. Molecular amplification techniques have advanced in sensitivity and throughput, enabling earlier detection in diverse sample matrices and supporting a broader set of clinical scenarios beyond traditional serology. Concurrently, point-of-care modalities and simplified antigen detection formats are converging toward near-patient use, lowering the threshold for timely diagnosis in outpatient clinics and neonatal wards where immediate therapeutic decisions are critical.

Regulatory pathways and laboratory accreditation standards are also reshaping product design and deployment. Manufacturers are prioritizing robust validation data, streamlined user workflows, and compatibility with laboratory information systems to meet hospital and reference laboratory requirements. Integration of quantitative readouts alongside qualitative determinations is increasing demand for assays that can support monitoring and therapeutic decision-making, particularly in transplant medicine and prenatal care. Meanwhile, sample type flexibility-expanding beyond whole blood to include urine, saliva, and tissue specimens-has broadened testing prospects and enabled less invasive diagnostic strategies.

These shifts are reinforced by health system priorities that place a premium on diagnostic stewardship, cost-effective screening protocols, and reduced time-to-result. As technologies converge, successful products will be those that balance analytical performance with usability, regulatory readiness, and clear clinical utility. The cumulative effect is a diagnostic environment that rewards interoperability, evidence-based claims, and development strategies that anticipate diverse end-user needs across acute care and community settings.

Implications of recent United States tariff measures on diagnostic supply chains, procurement strategies, and manufacturer sourcing resilience across cytomegalovirus testing

Recent tariff policies enacted by the United States have introduced an additional layer of complexity to the global supply chain for diagnostic components and instruments. Tariffs on imported reagents, instrument parts, and related consumables can increase landed costs for manufacturers and lab operators, prompting reassessment of sourcing strategies and inventory management. For organizations that rely on cross-border supply chains, these measures have heightened the need for supply diversification and nearshoring options to mitigate exposure to duty-related cost volatility.

In response, manufacturers and distributors have explored multiple mitigations including renegotiating supplier contracts, increasing inventory buffers, and accelerating qualification of alternative vendors in low-tariff jurisdictions. Laboratories and health systems have been compelled to evaluate total cost of ownership rather than unit price alone, factoring in logistics, customs delays, and potential downtime risks. Procurement departments are coordinating more closely with clinical stakeholders to prioritize critical assays and to sequence product rollouts in a manner that preserves clinical continuity while managing fiscal constraints.

Policy-driven cost pressures have also influenced strategic decisions around local manufacturing investment and product configuration. Some firms have opted to modularize instrument design to allow assembly or component sourcing in tariff-exempt locations, while others have pursued licensing or contract manufacturing arrangements to preserve market access. As a result, competitive differentiation is increasingly tied to supply chain resilience and the ability to maintain service level agreements under shifting trade conditions. For buyers and planners, the tariff environment underscores the importance of conducting scenario-based procurement planning and maintaining flexible contracts that can accommodate distribution or production changes without compromising clinical operations.

Comprehensive segmentation analysis revealing how product modality, test output, clinical application, end-user workflows, and sample matrices determine diagnostic value and adoption

Deconstructing CMV diagnostics by product, test type, application, end user, and sample type reveals how value and demand vary across clinical contexts and technology attributes. By product, the landscape includes antigen detection tests, nucleic acid amplification tests, and serological assays. Antigen detection formats differentiate by immunofluorescence and lateral flow approaches, each catering to different speed and sensitivity trade-offs; immunofluorescence assays typically serve centralized labs seeking higher analytical sensitivity while lateral flow antigen tests address rapid near-patient screening needs. Nucleic acid amplification encompasses digital polymerase chain reaction, isothermal amplification techniques, and real-time polymerase chain reaction; digital PCR offers absolute quantification useful for monitoring viral load, isothermal methods facilitate simplified instrumentation and rapid turnaround, and real-time PCR continues to be the workhorse for its balance of sensitivity, throughput, and regulatory familiarity. Serological assays, spanning chemiluminescent immunoassay, enzyme-linked immunosorbent assay, and lateral flow immunoassay formats, provide complementary information on host immune response and are central to screening and epidemiologic surveillance.

When viewed by test type, qualitative assays remain important for initial screening and binary diagnostic decisions, while quantitative assays increasingly inform monitoring, risk stratification, and therapeutic management. Application-driven differentiation shows that diagnostic use, donor screening, prenatal testing, and general population screening each place distinct demands on assay attributes such as limit of detection, sample throughput, and ease of use. End-user dynamics further stratify priorities: clinics and hospitals emphasize rapid turnaround and ease of integration into clinical workflows, diagnostic laboratories prioritize high-throughput automation and data management, and research institutes focus on assay flexibility, analytical sensitivity, and compatibility with downstream analyses.

Sample type variation-saliva, tissue, urine, and whole blood-creates opportunities for less invasive testing pathways as well as technical challenges for assay developers in validating performance equivalently across matrices. Urine and saliva offer noninvasive collection suited to neonatal and outpatient screening, whereas tissue and whole blood may be required for definitive diagnosis or for applications demanding high sensitivity. Across these axes, successful product strategies are those that align analytical strengths with the operational realities of target users and the clinical questions each assay seeks to answer.

Regional diagnostic landscapes and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated adoption pathways

Regional dynamics shape technology adoption, reimbursement practices, laboratory infrastructure, and clinical guidelines, creating distinct strategic imperatives across geographies. In the Americas, diagnostic ecosystems are characterized by well-established laboratory networks, adoption of molecular platforms, and clinical guidelines that favor early detection in high-risk populations. These systems reward assays that demonstrate clinical utility, scalability, and compatibility with electronic health records, while also demanding resilient supply chains and regulatory compliance.

In Europe, the Middle East & Africa region, heterogeneity in regulatory environments and healthcare infrastructure leads to varied adoption pathways. Some markets prioritize centralized testing with high-throughput molecular platforms, whereas others emphasize cost-effective, decentralized screening solutions that can function in lower-resource settings. Manufacturers pursuing these geographies must design flexible regulatory strategies and tiered product offerings to address divergent payer expectations and laboratory capabilities.

The Asia-Pacific region exhibits rapid uptake of innovative diagnostic technologies alongside diverse clinical needs and procurement models. Growing investments in public health screening programs, expanding access to tertiary care, and a strong emphasis on local manufacturing capacity shape commercial approaches. In several jurisdictions, expedited regulatory pathways and active public-private partnerships accelerate adoption, while supply chain localization efforts influence contractual and pricing dynamics. Across all regions, success depends on tailored evidence-generation, close engagement with clinical opinion leaders, and logistical models that account for regional distribution realities.

Competitive dynamics and strategic behaviors among platform incumbents, specialized innovators, and channel partners shaping assay availability and clinical validation

Competitive activity in the CMV testing arena reflects a mix of platform-focused manufacturers, specialized assay developers, and emerging innovators targeting niche clinical applications. Established diagnostic firms tend to compete on portfolio breadth, regulatory track record, and global distribution networks, offering integrated solutions that span high-throughput laboratory systems to point-of-care instrumentation. These incumbents invest in clinical validation studies, cross-platform compatibility, and lifecycle service agreements to maintain customer lock-in and to support hospital and reference laboratory requirements.

Specialized assay developers often differentiate through technical innovation such as enhanced sensitivity, simplified workflows for decentralized testing, or proprietary chemistries that reduce time-to-result. Partnerships between technology pioneers and larger distributors have become a common path to scale, enabling novel assays to reach broader clinical settings while leveraging established sales channels and regulatory expertise. New entrants focused on digital amplification methods or sample-to-answer platforms are reshaping expectations for quantitative performance and operational simplicity.

Across competitive dynamics, service and support models increasingly influence procurement decisions. Buyers value vendors that can provide installation, training, ongoing technical support, and robust quality assurance programs. Strategic behaviors such as co-development agreements with clinical centers, OEM partnerships, and targeted acquisitions are prevalent as firms seek to bolster capabilities quickly and to align product roadmaps with clinical demand signals. For stakeholders monitoring competitiveness, the critical lens is on how firms translate technical claims into validated clinical outcomes, deploy scalable commercial models, and maintain supply continuity under varied policy conditions.

Practical and prioritized actions for industry executives to enhance clinical credibility, resilience, and adoption of cytomegalovirus diagnostic solutions

Industry leaders can act decisively to capture clinical trust, accelerate adoption, and build resilient supply and commercial models in CMV testing. Prioritizing robust clinical validation studies that demonstrate actionable utility across intended applications will strengthen payer and provider confidence. Aligning product design with the operational realities of target end users-such as minimizing hands-on time for clinics or ensuring automation and throughput for diagnostic laboratories-will reduce barriers to adoption and support integration into clinical workflows.

Investing in supply chain resilience is essential; manufacturers should diversify sourcing, consider regional manufacturing partnerships, and design products that can be assembled across multiple jurisdictions to mitigate tariff exposure and logistical disruption. Collaborating with clinical thought leaders and public health authorities to generate guideline-aligned evidence will facilitate inclusion in screening and monitoring protocols. Additionally, companies should evaluate flexible pricing and service bundles that reflect total cost of ownership considerations for buyers, including reagent stability, instrument uptime guarantees, and software interoperability.

Finally, fostering partnerships that enable combined diagnostic and clinical management solutions-such as integrating quantitative viral load reporting with patient monitoring platforms-can create differentiated value for end users. Executing on these actions will require clear prioritization, cross-functional coordination between R&D, regulatory, and commercial teams, and disciplined investment in evidence generation and customer support infrastructure.

Transparent, reproducible research approach combining rigorous secondary evidence review with primary stakeholder interviews and scenario-based validation

This research utilized an evidence-driven methodology combining systematic secondary literature review with primary qualitative interviews to ensure balanced and reproducible findings. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers to map assay performance characteristics, recommended clinical workflows, and validation standards. Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and technology developers to capture firsthand perspectives on adoption drivers, operational constraints, and unmet needs.

Analytical frameworks were applied to synthesize insights across segmentation axes and geographies, ensuring that technology assessments were grounded in clinical applicability and laboratory realities. Triangulation techniques validated claims by cross-referencing instrument specifications, regulatory approvals, and clinical outcome studies. Scenario analysis was used to explore supply chain disruptions and policy shifts, while qualitative coding of interview responses identified recurring themes related to usability, evidence expectations, and service requirements.

All findings were subjected to internal peer review and cross-functional validation to enhance robustness and to reduce bias. The methodology emphasized transparency in source attribution and reproducibility of analytic steps, enabling stakeholders to assess the evidentiary basis for conclusions and to adapt frameworks for internal use.

Consolidated conclusions emphasizing validated innovation, operational resilience, and evidence-driven adoption as the pillars for effective cytomegalovirus diagnostic strategies

CMV diagnostics occupy a dynamic intersection of clinical need, technological innovation, and operational imperatives. Advances in molecular amplification and point-of-care antigen detection are expanding the settings and use cases where timely CMV identification can materially influence outcomes for neonates, transplant recipients, and pregnant patients. At the same time, regulatory rigor, supply chain constraints, and regional heterogeneity demand that developers and adopters pursue evidence-driven, flexible strategies that prioritize clinical utility and service continuity.

Decision-makers should orient product development and procurement around demonstrable improvements in patient management, ease of integration into existing workflows, and resilience against policy- or logistics-driven disruptions. By doing so, stakeholders can ensure that investments in diagnostics translate into measurable clinical benefits and sustainable commercial returns. The net effect is a landscape that rewards validated innovation, operational pragmatism, and collaborative approaches to evidence generation and distribution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cytomegalovirus Tests Market, by Product

  • 8.1. Antigen Detection Test
    • 8.1.1. Immunofluorescence Assay
    • 8.1.2. Lateral Flow Assay
  • 8.2. Nucleic Acid Amplification Test
    • 8.2.1. Digital Polymerase Chain Reaction
    • 8.2.2. Isothermal Amplification
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Serological Assay
    • 8.3.1. Chemiluminescent Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Immunoassay

9. Cytomegalovirus Tests Market, by Test Type

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Cytomegalovirus Tests Market, by Sample Type

  • 10.1. Saliva
  • 10.2. Tissue
  • 10.3. Urine
  • 10.4. Whole Blood

11. Cytomegalovirus Tests Market, by Application

  • 11.1. Diagnostic
  • 11.2. Donor Screening
  • 11.3. Prenatal Testing
  • 11.4. Screening

12. Cytomegalovirus Tests Market, by End User

  • 12.1. Clinic
  • 12.2. Diagnostic Laboratory
  • 12.3. Hospital
  • 12.4. Research Institute

13. Cytomegalovirus Tests Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cytomegalovirus Tests Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cytomegalovirus Tests Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cytomegalovirus Tests Market

17. China Cytomegalovirus Tests Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbexa Ltd.
  • 18.6. Abbott Laboratories
  • 18.7. Accubiotech Co., Ltd
  • 18.8. AdvaCare Pharma USA
  • 18.9. Agilent Technologies, Inc.
  • 18.10. Atlas Medical GmbH
  • 18.11. Bio-Rad Laboratories, Inc.
  • 18.12. Biogenix Inc. Pvt. Ltd.
  • 18.13. CLONIT srl
  • 18.14. Creative Diagnostics
  • 18.15. CTK Biotech Inc. by SSI Diagnostica A/S
  • 18.16. Diasorin S.p.A.
  • 18.17. Elabscience Bionovation Inc.
  • 18.18. F. Hoffmann-La Roche Ltd.
  • 18.19. Hangzhou Realy Tech Co., Ltd.
  • 18.20. Intec Products, Inc.
  • 18.21. IQ Products B.V.
  • 18.22. Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • 18.23. Meridian Bioscience, Inc. by SD Biosensor
  • 18.24. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)